The Parkinson’s UK Brain Bank is evolving — using technology to help piece together the mysteries of Parkinson’s deep within the brain.

Researchers show changes in vision could predict the development of thinking and memory problems in people with Parkinson’s.

We take a look at some recent major pharma investments to drive forward new therapies for Parkinson’s.

As we say so long to 2020, and hope that 2021 might be a little kinder to all, we look back on some of the highlights. We reflect on the…

Balance and falls are a major concern for people with Parkinson’s. Find out how new research aims to address this through a new device.

It’s more than just drugs that are being investigated to find better treatments for Parkinson's. What about non-invasive devices?

Have you come across advice that those with Parkinson’s should avoid too much refined sugar, or perhaps you’re heard of a link with diabetes

Undergoing brain surgery may sound dramatic, but for around 300 people with Parkinson’s in the UK each year it is a lifeline…

The potential link between pesticides and Parkinson’s is something we get asked about a lot at Parkinson’s UK. Here’s what you need to know…

Studies highlight the potential of deep brain stimulation to slow progression and improve non-motor symptoms for people with Parkinson’s.

New one-step process converts cells inside the brain into dopamine-producing cells to replace those lost in Parkinson’s.

Dr Arthur Roach, Director of Research at Parkinson’s UK, shares how the charity is driving forward research during the coronavirus…

In this blog, we review the latest update from the trials of prasinezumab — a vaccine therapy for Parkinson’s — and reflect on how COVID-19…

The findings may help explain why some dopamine-producing cells are more susceptible to Parkinson’s than others.

Parkinson’s won’t stop during this pandemic. Neither can the search for better treatments and a cure.

Initial data from the latest phase 2 study of a vaccine for Parkinson’s gives an insight into the trial. We find out how the therapy works.

A phase 2 trial of an experimental drug that aimed to reduce side effects of levodopa has shown disappointing results.

We investigate a new type of deep brain stimulation that could provide better symptom management.

It may be vital to look beyond dopamine to find a way to slow the progression of Parkinson’s.

Chronic pain affects more than half of those with Parkinson’s — but why some people experience this and others don’t is a mystery.